Drug-eluting stent: a review and update
Thein Htay, Ming W LiuDivision of Cardiovascular Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USAAbstract: The development of stent has been a major advance in the treatment of obstructive coronary artery disease since the introductio...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2005-12-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | https://www.dovepress.com/drug-eluting-stent-a-review-and-update-peer-reviewed-article-VHRM |
| _version_ | 1819268507749056512 |
|---|---|
| author | Thein Htay Ming W Liu |
| author_facet | Thein Htay Ming W Liu |
| author_sort | Thein Htay |
| collection | DOAJ |
| description | Thein Htay, Ming W LiuDivision of Cardiovascular Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USAAbstract: The development of stent has been a major advance in the treatment of obstructive coronary artery disease since the introduction of balloon angioplasty. However, neointimal hyperplasia occurring within the stent leading to in-stent restenosis is a main obstacle in the long-term success of percutaneous coronary intervention (PCI). The recent introduction of drug-eluting stents (DES) contributes a major breakthrough to interventional cardiology. Many large randomized clinical trials using DES have shown a remarkable reduction in angiographic restenosis and target vessel revascularization when compared with bare metal stents. The results of these trials also appear to be supported by evidence from everyday practice and noncontrolled clinical trials. However, the expanded applications of DES, especially in treating complex lesions such as left main trunk, bifurcation, saphenous vein graft lesions, or in-stent restenosis, are still under evaluation with ongoing studies. With the availability of different types of DES in the market, the issue of cost should not be a deterrent and DES will eventually be an economically viable option for all patients. The adoption of DES in all percutaneous coronary intervention may become a reality in the near future. In this review article, we summarize the recent development and progress of DES as well as compare and update the results of clinical trials.Keywords: drug-eluting stent, percutaneous transluminal coronary angioplasty, in-stent restenosis |
| first_indexed | 2024-12-23T21:34:10Z |
| format | Article |
| id | doaj.art-ce01eeb6212e4e07b7003fcc79ee5007 |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-12-23T21:34:10Z |
| publishDate | 2005-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-ce01eeb6212e4e07b7003fcc79ee50072022-12-21T17:30:22ZengDove Medical PressVascular Health and Risk Management1178-20482005-12-01Volume 12632761387Drug-eluting stent: a review and updateThein HtayMing W LiuThein Htay, Ming W LiuDivision of Cardiovascular Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USAAbstract: The development of stent has been a major advance in the treatment of obstructive coronary artery disease since the introduction of balloon angioplasty. However, neointimal hyperplasia occurring within the stent leading to in-stent restenosis is a main obstacle in the long-term success of percutaneous coronary intervention (PCI). The recent introduction of drug-eluting stents (DES) contributes a major breakthrough to interventional cardiology. Many large randomized clinical trials using DES have shown a remarkable reduction in angiographic restenosis and target vessel revascularization when compared with bare metal stents. The results of these trials also appear to be supported by evidence from everyday practice and noncontrolled clinical trials. However, the expanded applications of DES, especially in treating complex lesions such as left main trunk, bifurcation, saphenous vein graft lesions, or in-stent restenosis, are still under evaluation with ongoing studies. With the availability of different types of DES in the market, the issue of cost should not be a deterrent and DES will eventually be an economically viable option for all patients. The adoption of DES in all percutaneous coronary intervention may become a reality in the near future. In this review article, we summarize the recent development and progress of DES as well as compare and update the results of clinical trials.Keywords: drug-eluting stent, percutaneous transluminal coronary angioplasty, in-stent restenosishttps://www.dovepress.com/drug-eluting-stent-a-review-and-update-peer-reviewed-article-VHRM |
| spellingShingle | Thein Htay Ming W Liu Drug-eluting stent: a review and update Vascular Health and Risk Management |
| title | Drug-eluting stent: a review and update |
| title_full | Drug-eluting stent: a review and update |
| title_fullStr | Drug-eluting stent: a review and update |
| title_full_unstemmed | Drug-eluting stent: a review and update |
| title_short | Drug-eluting stent: a review and update |
| title_sort | drug eluting stent a review and update |
| url | https://www.dovepress.com/drug-eluting-stent-a-review-and-update-peer-reviewed-article-VHRM |
| work_keys_str_mv | AT theinhtay drugelutingstentareviewandupdate AT mingwliu drugelutingstentareviewandupdate |